A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus

Thomas W. Geisbert, Kathryn Bobb, Viktoriya Borisevich, Joan B. Geisbert, Krystle N. Agans, Robert W. Cross, Abhishek N. Prasad, Karla A. Fenton, Hao Yu, Timothy R. Fouts, Christopher C. Broder, Antony S. Dimitrov

Research output: Contribution to journalArticlepeer-review

Abstract

Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in use in Australia since 2012. Based on the same immunogen, the Hendra virus attachment glycoprotein ectodomain, a subunit vaccine formulation for use in people is now in a Phase I clinical trial. We report that a single dose vaccination regimen of this human vaccine formulation protects against otherwise lethal challenges of either Hendra or Nipah virus in a nonhuman primate model. The protection against the Nipah Bangladesh strain begins as soon as 7 days post immunization with low dose of 0.1 mg protein subunit. Our data suggest this human vaccine could be utilized as efficient emergency vaccine to disrupt potential spreading of Nipah disease in an outbreak setting.

Original languageEnglish (US)
Article number23
Journalnpj Vaccines
Volume6
Issue number1
DOIs
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus'. Together they form a unique fingerprint.

Cite this